Age Eligibility: Ages 55 to 89 years
The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates. The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.
Age Eligibility: Ages 50 to 80 years
A new approach to dementia treatment- targeting the proteins connected to memory loss. Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B. Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.
Age Eligibility: Ages 55 to 80 years
This study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.
Age Eligibility: Ages 60 years or older
The purpose of this clinical trial is to study heart function in relation to brain health.
Age Eligibility: Ages 55 years or older
The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment.
Age Eligibility: 45 to 80 years
Studying COVID-19’s long-term neurological and psychological impacts.
Age Eligibility: Between the ages of 65 and 90 years
The results of this study will be used to develop and validate a predictive risk model to inform future care.
Must be at least 60 years old and have a legally authorized representative to attend all study visits.
A treatment to remove dysregulated cells found in mild cognitive impairment and Alzheimer’s disease.
Age Eligibility: Age 62 or older, identify as Mexican American and has reliable broadband internet connection.
To learn more about why dementia is disproportionately affecting Hispanics, our researchers are recruiting volunteers to learn how to better serve this underrepresented population.
Age Eligibility: Ages 60-90 years old, with or without memory-loss concerns.
During four annual assessments, we will compare your blood biomarkers and brain health to verify biomarkers as an accessible and affordable way to learn healthy aging from signs of dementia.